[go: up one dir, main page]

AR017896A1 - Derivados de la n-fenilamida y n-piridilamida, procedimiento para prepararlos, empleo de los mismos para preparar un medicamento, dicho medicamentocomposicion farmaceutica que los contiene e intermediarios de sintesis - Google Patents

Derivados de la n-fenilamida y n-piridilamida, procedimiento para prepararlos, empleo de los mismos para preparar un medicamento, dicho medicamentocomposicion farmaceutica que los contiene e intermediarios de sintesis

Info

Publication number
AR017896A1
AR017896A1 ARP980106472A ARP980106472A AR017896A1 AR 017896 A1 AR017896 A1 AR 017896A1 AR P980106472 A ARP980106472 A AR P980106472A AR P980106472 A ARP980106472 A AR P980106472A AR 017896 A1 AR017896 A1 AR 017896A1
Authority
AR
Argentina
Prior art keywords
alkyl
same
different
represent
prepare
Prior art date
Application number
ARP980106472A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR017896A1 publication Critical patent/AR017896A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06Benzothiopyrans; Hydrogenated benzothiopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

Derivados de la N-fenilamida y N-piridilamida de formula (I), en la cual X representa O, S o CH2; R1 y R2 pueden ser iguales o diferentes y representanhidrogeno, alquilo C1-6 o cicloalquilo C3-8, o bien R1 y R2 forman, junto con el átomo de carbonoq ue los sostiene, un cicloalquilo C3-8; R3 representaarilo C6-12 eventualmente sustituido con uno o más radicales Y que pueden ser iguales o diferentes; o heteroarilo de 5 a 7 miembros que contiene 1 a 3heteroátomos endocíclicos elegidos entre elO, S y N, y que se encuentra eventualmente sustituido con uno o más radicales Y que pueden ser igualeso diferentes; Y representa halogeno, un grupo de alquilo C1-6 eventualmente sustituido con uno o más halogenos, un grupo de alcoxi C1-6eventualmentesu stituido con uno o más halogenos, un grupo de alquiltio C1-6 eventualmente sustituido con uno o más halogenos, acil C1-7 amino, aciloxi C1-3,hidroxilo, nitro, ciano, amino, alquil C1-6 amino, dialquil C1-6 amino, pirrolidino,piperidino, morfolino, alquil C1-4 sulfonilamino, alcoxi C2-5carbonilo, carboxilo, alquil C2-6 carbonilo, carbamoilo, alquil C2-5 carbamoilo, dialquil C2-5 carbamoilo o alquil C1-6 sulfonilo; R4 y R5 pueden seriguales o diferentes y representan unradical Y o alternativame nte un átomo de hidrogeno; Ar es uno de los grupos A, B o C; T1 y T2 pueden ser igualeso diferentes y representan halogeno, alcoxi C1-6, alquil C1-6 tio o alquilo C1-6; T representa un átomo de hidrogeno o alquilo C1-6; T3y T4 pueden seriguales o di ferentes y representan alquilo C1-6, alcoxi C1-6, alquil C1-6 tio, aril C6-12 tio, alcoxi C1-6 carbonilo, alquil C1-6 carbonilo, aril C6-12carbonilo, o -(CH2)p-OR en donde p es 1, 2, 3 o 4 y R representa alquilo C2-3; R6y R7 representan individualme nte un átomo de hidrogeno, o bienR6 y R7 forman juntos un enlace; Z representa ya sea (i) el grupo divalente -CHR9- en el cual R9 es un átomo de hidrogeno o un grupo de alquilo C1-6; o(ii) el grupo divalente -CHR10-CHR11- en el cual R10 y R11 forman juntos un enlace de manera tal que Z sea -CH=CH-, o bien R10 y R11 pueden ser iguales o
ARP980106472A 1997-12-23 1998-12-18 Derivados de la n-fenilamida y n-piridilamida, procedimiento para prepararlos, empleo de los mismos para preparar un medicamento, dicho medicamentocomposicion farmaceutica que los contiene e intermediarios de sintesis AR017896A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716399A FR2772761B1 (fr) 1997-12-23 1997-12-23 Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
AR017896A1 true AR017896A1 (es) 2001-10-24

Family

ID=9515039

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106472A AR017896A1 (es) 1997-12-23 1998-12-18 Derivados de la n-fenilamida y n-piridilamida, procedimiento para prepararlos, empleo de los mismos para preparar un medicamento, dicho medicamentocomposicion farmaceutica que los contiene e intermediarios de sintesis

Country Status (19)

Country Link
US (2) US6339097B1 (es)
EP (1) EP1040109A1 (es)
JP (1) JP2001527073A (es)
KR (1) KR20010033414A (es)
CN (1) CN1283196A (es)
AR (1) AR017896A1 (es)
AU (1) AU751291B2 (es)
BR (1) BR9813712A (es)
CA (1) CA2316382A1 (es)
FR (1) FR2772761B1 (es)
HU (1) HUP0004546A3 (es)
ID (1) ID26506A (es)
MY (1) MY132969A (es)
NO (1) NO20003290L (es)
PL (1) PL341241A1 (es)
RU (1) RU2214409C2 (es)
SK (1) SK9312000A3 (es)
WO (1) WO1999033825A1 (es)
ZA (1) ZA9811795B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
AU2002221116A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved water-solubility
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
SI2220076T1 (sl) 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
US8217188B2 (en) * 2008-08-27 2012-07-10 Corning Incorporated 2H-chromenes annelated at C5-C6 and methods of making and using thereof
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CN117304157A (zh) * 2018-02-27 2023-12-29 阿塔克斯生物制药有限公司 作为tcr-nck相互作用的抑制剂的色烯衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87019A (en) * 1987-07-10 1993-07-08 Hoffmann La Roche Substituted alkene carboxamides and derivatives, their manufacture and pharmaceutical compositions containing them
FR2642065B1 (fr) * 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
CA2026389A1 (en) * 1989-09-29 1991-03-30 Hideo Nakai Chromene or thiochromene derivatives, process for preparing the same and intermediate therefor
DE69110828T2 (de) * 1990-10-16 1995-11-30 Takeda Chemical Industries Ltd Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
US5491152A (en) * 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
HUP0302825A3 (en) * 2000-07-13 2005-02-28 Takeda Pharmaceutical Lipid-rich plaque inhibitors

Also Published As

Publication number Publication date
FR2772761B1 (fr) 2000-05-26
US20020068739A1 (en) 2002-06-06
FR2772761A1 (fr) 1999-06-25
RU2214409C2 (ru) 2003-10-20
CA2316382A1 (en) 1999-07-08
PL341241A1 (en) 2001-03-26
US6509362B2 (en) 2003-01-21
HUP0004546A2 (hu) 2001-08-28
EP1040109A1 (en) 2000-10-04
WO1999033825A8 (en) 1999-08-26
AU2270999A (en) 1999-07-19
KR20010033414A (ko) 2001-04-25
NO20003290L (no) 2000-08-22
SK9312000A3 (en) 2001-04-09
CN1283196A (zh) 2001-02-07
US6339097B1 (en) 2002-01-15
BR9813712A (pt) 2000-12-12
WO1999033825A1 (en) 1999-07-08
MY132969A (en) 2007-10-31
HUP0004546A3 (en) 2002-12-28
ID26506A (id) 2001-01-11
ZA9811795B (en) 1999-06-22
AU751291B2 (en) 2002-08-08
NO20003290D0 (no) 2000-06-22
JP2001527073A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
AR017896A1 (es) Derivados de la n-fenilamida y n-piridilamida, procedimiento para prepararlos, empleo de los mismos para preparar un medicamento, dicho medicamentocomposicion farmaceutica que los contiene e intermediarios de sintesis
AR055071A1 (es) Derivados de pirrolo (3,2 - b) pirimidina. composiciones farmaceuticas.
AR013199A1 (es) Compuesto sulfonamidas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de los mismos para la fabricacionde un medicamento
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
DK0481522T3 (da) Nye mercaptoacetylamid-derivater anvendelige som inhibitorer af enkephalinase og ACE
FI942769A0 (fi) Antianginaaliset kinatsolinonit
ATE47845T1 (de) Guanidin-derivate.
EP1780209A4 (en) OXIMESTER CONNECTION AND PHOTOPOLYMERIZATION INITIATOR CONTAINING SUCH A COMPOUND
AR049543A1 (es) Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica
ES2294313T3 (es) Derivados de piridina como moduladores del receptor cb2.
FI955316A0 (fi) Vitamiini D:n amidijohdannaisia
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR042629A1 (es) Derivados de tetrahidroquinolina, composiciones farmaceuticas que los incluyen y su uso como medicamento.
CO5261507A1 (es) Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos
DE69321609D1 (de) Piperazinderivate
FI864618A0 (fi) Nya 3-oxadiazol- och 3-karboksylsyra- -karbolinderivat, deras framstaellning och deras anvaendning som laekemedel.
ES2177275T3 (es) Derivados de oxadiazolina y su uso como insecticidas.
ATE325788T1 (de) Kristalle von vitamin d derivaten und verfahren zu ihrer herstellung
DE68908643D1 (de) Mercapto-phenylalkanoylaminosäure-Amide, deren Herstellung und deren Verwendung als Collagenase-Inhibitoren.
DE69525633D1 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
DE602004007181D1 (de) 2,4,6-tris(4'aminobenzaldineopentylmalonat)-s-triazin, dieser enthaltenden Sonnenschutzzusammensetzungen und dessen Verwendungen
AR050032A1 (es) Derivados de acido benzoico como inhibidores no nucleosidos de la transcriptasa inversa
DE69217717D1 (de) Benzopyranderivate und Verfahren zu deren Herstellung
AR017731A1 (es) Compuestos y procedimiento para alquilar sulfonamidas impedidas estericamente
ATE156125T1 (de) Substituierte alkylpiperidine und deren verwendung als inhibitoren der cholesterolsynthese

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure